论文部分内容阅读
目的:探讨动态血糖监测系统(CGMS)联合胰岛素泵持续皮下输注胰岛素(CSII)治疗初诊重症2型糖尿病(T2DM)的有效性及安全性.方法:48例初诊重症T2DM病人分为试验组与对照组,试验组CGMS与CSII联合应用,当皮下探头信号衰减时改为每日7次指尖血糖监测指导CSII直至血糖达标;对照组始终用每日7次指尖血糖监测指导CSII血糖达标.观察两组血糖达标所需天数、全天胰岛素用量、低血糖发生率和各时间点血糖来评价治疗的有效性及安全性.结果:试验组血糖达标所需天数、全天胰岛素用量、低血糖发生率和各时间点血糖均低于对照组.结论:试验组治疗初诊重症T2DM有效性及安全性优于对照组.
Objective: To investigate the efficacy and safety of CGMS combined with continuous subcutaneous infusion of insulin pump (CSII) in the treatment of newly diagnosed type 2 diabetes mellitus (T2DM) .Methods: 48 cases of newly diagnosed severe type 2 diabetes were divided into experimental group and control group The control group and the test group were used in combination with CSII. When the subcutaneous probe signal was decayed, it was changed to seven times per day. The control group was guided by CSII until the blood glucose reached the standard. In the control group, the blood glucose level of the CSII was guided by fingertip blood glucose monitoring seven times a day. The duration of blood glucose, the amount of insulin during the whole day, the incidence of hypoglycemia and blood glucose at each time point were used to evaluate the efficacy and safety of treatment.Results: The incidence and the blood glucose at each time point were lower than the control group.Conclusion: The experimental group is better than the control group in the treatment of critically ill T2DM.